ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.515,79
0,28%
S&P 500
5.321,80
0,35%
US Dollar vs BRL
5,0962
-0,14%
Bitcoin
67.793,75
2,46%
Brent Oil
83,49
-0,13%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kodiak Sciences Inc (KOD)

  7. Kodiak Sciences Inc (KOD) Notícias

KOD

Kodiak Sciences (KOD)

Kodiak Sciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KOD
DataHoraFonteTítuloCódigoCompanhia
15/05/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KODKodiak Sciences Inc
15/05/202417:01PR Newswire (US)Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KODKodiak Sciences Inc
13/05/202420:32PR Newswire (US)Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic RetinopathyNASDAQ:KODKodiak Sciences Inc
02/05/202417:30PR Newswire (US)Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) PlatformNASDAQ:KODKodiak Sciences Inc
28/03/202407:30PR Newswire (US)Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KODKodiak Sciences Inc
26/03/202407:15PR Newswire (US)Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024NASDAQ:KODKodiak Sciences Inc
14/02/202418:23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KODKodiak Sciences Inc
30/01/202408:30PR Newswire (US)Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual MeetingNASDAQ:KODKodiak Sciences Inc
04/01/202418:15PR Newswire (US)Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KODKodiak Sciences Inc
21/11/202318:15PR Newswire (US)Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:KODKodiak Sciences Inc
14/11/202318:01PR Newswire (US)Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:KODKodiak Sciences Inc
06/11/202307:00PR Newswire (US)Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submissionNASDAQ:KODKodiak Sciences Inc
02/11/202300:21PR Newswire (US)KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETINGNASDAQ:KODKodiak Sciences Inc
11/10/202307:00PR Newswire (US)Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina SocietyNASDAQ:KODKodiak Sciences Inc
08/09/202307:00PR Newswire (US)Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:KODKodiak Sciences Inc
07/09/202307:00PR Newswire (US)New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusionNASDAQ:KODKodiak Sciences Inc
14/08/202317:33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KODKodiak Sciences Inc
14/08/202317:01PR Newswire (US)Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:KODKodiak Sciences Inc
24/07/202307:00PR Newswire (US)Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development ProgramNASDAQ:KODKodiak Sciences Inc
03/07/202317:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KODKodiak Sciences Inc
27/06/202318:36Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KODKodiak Sciences Inc
07/06/202317:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KODKodiak Sciences Inc
05/06/202307:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:KODKodiak Sciences Inc
30/05/202317:15PR Newswire (US)Kodiak Sciences to Present at Upcoming Investor ConferencesNASDAQ:KODKodiak Sciences Inc
15/05/202318:08Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:KODKodiak Sciences Inc
15/05/202317:23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KODKodiak Sciences Inc
15/05/202317:01PR Newswire (US)Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:KODKodiak Sciences Inc
25/04/202317:46Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KODKodiak Sciences Inc
25/04/202317:05Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KODKodiak Sciences Inc
25/04/202317:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KODKodiak Sciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KOD

Seu Histórico Recente

BIT
NSCIT5443477
Rocky SPV
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados